Aktienanalyse zu Arrowhead Pharmaceuticals, Inc. (ARWR)ARWRArrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arrowhead Pharmaceuticals Inc is currently a hold. The stock is priced at $55.90, significantly below the analyst price targets of $74 from Goldman Sachs and $108 from Citi, indicating potential upside. However, the RSI is at a very low 17.125, suggesting the stock is oversold, which could lead to a rebound. The company has shown promising early trial results for its Alzheimer's drug, ARO-MAPT, with a 73% reduction in tau protein levels, which could drive future growth. However, the risk remains high as the stock has a forward P/E of 111.11 and has seen a 10.92% decline over the past five days, indicating volatility and uncertainty in the market.